Tumor vascular infarction: prospects and challenges

International Journal of Hematology

Volumn 105, Issue 3, 2017, Pages 244-256

  Jahanban Esfahlan, Rana ^a   Seidi, Khaled ^a   Zarghami, Nosratollah ^a,b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Incomplete thrombosis; MazF; Novel strategy; Tissue factor (TF); Tumor vascular infarction; Tumor vascular targeting

Indexed keywords

ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; THROMBOPLASTIN; VASCULAR TARGETING AGENT;

APOPTOSIS; CANCER THERAPY; DRUG MECHANISM; FIBRIN CLOT; HUMAN; INFARCTION; NONHUMAN; REVIEW; RISK BENEFIT ANALYSIS; THROMBOSIS; TUMOR VASCULAR INFARCTION; TUMOR VASCULARIZATION; ANIMAL; BLOOD; MOUSE; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; THROMBOPLASTIN; THROMBOSIS;

EID: 85007578556     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-016-2171-3     Document Type: Review

References (61)

1. Auerbach W, Auerbach R. Angiogenesis inhibition: a review. Pharmacol Ther. 1994;63:265–311.
2. Augustin HG. Antiangiogenic tumour therapy: will it work? TiPS. 1998;19:216–22.
3. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature (London). 2000;407:249–57.
4. Cesca M, Bizzaro F, Zucchetti M, Giavazzi R. Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents. Frontiers oncology. 2013;3:1–7.
5. Fujita K, Sano D, Kimura M, Yamashita K, Kawakami M, Ishiguro Y, et al. Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma. Oncol Lett. 2007;18:47–51.
6. Gaya AM, Rustin GJ. Vascular disrupting agents: a new class of drug in cancer therapy. Clin Oncol (R Coll Radiol). 2005;17(4):277–90.
7. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science. 1997;275(5299):547–50.
8. Liang W, Ni Y, Chen F. Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions. Oncotarget. 2016;7:15444–59.
9. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer. 2005;5(6):423–35. doi:10.1038/nrc1628.
10. Wahl O, Oswald M, Tretzel L, Herres E, Arend J, Efferth T. Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products. Curr Med Chem. 2011;18:3136–55.
11. Wu XY, Ma W, Gurung K, Guo CH. Mechanisms of tumor resistance to small -molecule vascular disrupting agents: treatment and rationale of combination therapy. J Formos Med Assoc. 2013;112(112):115–24.
12. Teicher BA. Flipping the wound that doesn’t heal: the upside of coagulation in cancer. Blood. 2009;113(20):4826–8.
13. van Beijnum JR, Nowak-Sliwinska P, Huijbers EJ, Thijssen VL, Griffioen AW. The great escape; the hallmarks of resistance to antiangiogenic therapy. Pharmacol Rev. 2015;67(2):441–61.
14. De Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012;13(12):1225–33.
15. Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res. 2007;74(2–3):72–84.
16. El-Kenawi AE, El-Remessy AB. Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharmacol. 2013;170:712–29.
17. Patterson DM, Rustin GJS. Vascular Damaging Agents. Clinical Oncology. 2007;19(443):e56.
18. Djeha H, Shah K, McGeever G, Dobinson D, Green C. Combination of the vascular disrupting agent DMXAA (AS1404) with bevacizumab and paclitaxel produces synergistic antitumor activity in lung cancer xenografts. Proc Amer Assoc Cancer Res. 2007;48 (abstract 4642).
19. Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, et al. Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol. 2015;35(Suppl):S224–43.
20. McKeage MJ, Baguley BC. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer. 2010;116(8):1859–71.
21. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev. 1990;9:267–82.
22. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res. 2004;10(2):415–27.
23. Kessler T, Bieker R, Padro T, Schwoppe C, Persigehl T, Bremer C, et al. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. Clin Cancer Res. 2005;11(17):6317–24.
24. Fabbrini M, Trachsel E, Soldani P, Bindi S, Alessi P, Bracci L, et al. Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate. Int J Cancer. 2006;118(7):1805–13.
25. Su MY, Samoszuk MK, Wang J, Nalcioglu O. Assessment of protamine—induced thrombosis of tumor vessels for cancer therapy using dynamic contrast-enhanced MRI. NMR Biomed. 2002;15:106–13.
26. Guba M, Yezhelyev M, Eichhorn ME, Schmid G, Ischenko I, Papyan A, et al. Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood. 2005;105(11):4463–9.
27. Nilsson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res. 2001;61:711–6.
28. Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorp PE. Infarction of solid Hodgkin’s tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res. 1998;58:4646–53.
29. Liu C, Huang H, Donate F, Dickinson C, Santucci R, El-Sheikh A, et al. Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res. 2002;62(19):5470–5.
30. Hu P, Yan J, Sharifi J, Bai T, Khawli LA, Epstein AL. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer Res. 2003;63(16):5046–53.
31. Bieker R, Kessler T, Schwoppe C, Padro T, Persigehl T, Bremer C, et al. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood. 2009;113(20):5019–27.
32. Corti A, Curnis F. Tumor vasculature targeting through NGR peptide-based drug delivery systems. Curr Pharm Biotechnol. 2011;12(8):1128–34.
33. Dreischaluck J, Schwoppe C, Spiekers T, Kessler T, Tiemann K, Liersch R, et al. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile. Int J Oncol. 2010;37:1389–97.
34. Huang FY, Li YN, Wang H, Huang YH, Lin YY, Tan GH. A fusion protein containing murine vascular endothelial growth factor and tissue factor induces thrombogenesis and suppression of tumor growth in a colon carcinoma model. J Zhejiang Univ Sci B. 2008;9(8):602–9.
35. Huang ZJ, Zhao Y, Luo WY, You J, Li SW, Yi WC, et al. Targeting the vasculature of colorectal carcinoma with a fused protein of (RGD)(3)-tTF. Sci World J. 2013;2013:637086.
36. Brand C, Schliemann C, Ring J, Kessler T, Bäumer S, Angenendt L, et al. NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor. Oncotarget. 2016;7(6):6774–89.
37. Giuliano S, Pagès G. Mechanisms of resistance to anti-angiogenesis therapies. Biochimie. 2013;95:1110e9.
38. Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014;17:471–94.
39. Geddings JE, Mackman N. Tumor-derived tissue factor—positive microparticles and venous thrombosis in cancer patients. Blood. 2013;122(11):1873–80.
40. Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res. 2009;15(22):6830–40.
41. Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA. 2000;97(10):5255–60.
42. Chen J, Bierhaus A, Schiekofer S, Andrassy M, Chen B, Stern DM, et al. Tissue factor–a receptor involved in the control of cellular properties, including angiogenesis. Thromb Haemost. 2001;86(1):334–45.
43. Jiang X, Bailly MA, Panetti TS, Cappello M, Konigsberg WH, Bromberg ME. Formation of tissue factor-factor VIIa-factor Xa complex promotes cellular signaling and migration of human breast cancer cells. J Thromb Haemost. 2004;2(1):93–101.
44. Yokota N, Zarpellon A, Chakrabarty S, Bogdanov VY, Gruber A, Castellino FJ, et al. Contributions of thrombin targets to tissue factor-dependent metastasis in hyperthrombotic mice. J Thromb Haemost. 2014;12(1):71–81.
45. Patyar S, Joshi R, Prasad Byrav D, Prakash A, Medhi B, Das B. Bacteria in cancer therapy: a novel experimental strategy. J Biomed Sci. 2010;17(21):1–9.
46. Suzuki M, Mao L, Inouye M. Single protein production (SPP) system in Escherichia coli. Nat Protocol. 2007;2(7):1802–10.
47. Zhang Y, Zhang J, Hara H, Kato I, Inouye M. Insights into the mRNA cleavage mechanism by MazF, an mRNA interferase. J Biol Chem. 2005;280:3143–50.
48. Zhang Y, Zhang J, Hoeflich KP, Ikura M, Qing G, Inouye M. MazF cleaves cellular mRNAs specifically at ACA to block protein synthesis in Escherichia coli. Mol Cell. 2003;12:913–23.
49. Muñoz-Gómez AJ, Santos-Sierra S, Berzal-Herranz A, Lemonnier M, Díaz-Orejas R. Insights into the specificity of RNA cleavage by the Escherichia coli MazF toxin. FEBS Lett. 2003;567:316–20.
50. + T cells. Hum Gene Ther Methods. 2013;24(2):94–103.
51. (+) T Cells Modified by the Endoribonuclease MazF are safe and can persist in SHIV-infected Rhesus Macaques. Mol Therapy Nucleic Acids. 2014;3(6):e168.
52. Inouye M. The discovery of mRNA interferases: implication in bacterial physiology and application to biotechnology. J Cell Physiol. 2006;209:670–6.
53. Shimazu T, Mirochnitchenko O, Phadtare S, Inouye M. Regression of solid tumors by induction of MazF, a bacterial mRNA endoribonuclease. J Mol Microbiol Biotechnol. 2014;24(4):228–33.
54. Bermudes D, Zheng L, King IC. Live bacteria as anticancer agents and tumor-selective protein delivery vectors. Curr Opin Drug Discov Dev. 2002;5(2):194–9.
55. Engelberg-Kulka H, Hazan R, Amitai S. mazEF. A chromosomal toxin-antitoxin module that triggers programmed cell death in bacteria. J Cell Sci. 2005;118:4327–32.
56. Hatefi A, Canine BF. Perspectives in vector development for systemic cancer gene therapy. Gene Ther Mol Biol. 2009;13(A):15–9.
57. Zhao M, Yang M, Li XM, Jiang P, Baranov E, Li S, et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. PNAS. 2005;102(3):755–60.
58. Kim S, Castro F, Paterson Y, Gravekamp C. High efficacy of a Listeria based vaccine against metastatic breast cancer reveals a dual mode of action. Cancer Res. 2009;69(14):5860–6.
59. Cheng CMLY, Chuang KH, Hung WC, Shiea J, Su YC, et al. Tumor-targeting prodrug-activating bacteria for cancer therapy. Cancer Gene Ther. 2008;15:393–401.
60. Friedlos F, Lehouritis P, Ogilvie L, Hedley D, Davies L, Bermudes D, et al. Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy. Clin Cancer Res. 2008;14:4259–66.
61. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. PNAS. 2001;98(26):5155–15160.